EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy.
Bao Y, Oguz G, Lee WC, Lee PL, Ghosh K, Li J, Wang P, Lobie PE, Ehmsen S, Ditzel HJ, Wong A, Tan EY, Lee SC, Yu Q.
Bao Y, et al. Among authors: ehmsen s.
Nat Commun. 2020 Nov 18;11(1):5878. doi: 10.1038/s41467-020-19704-x.
Nat Commun. 2020.
PMID: 33208750
Free PMC article.